A Phase 4 interventional study of Fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% and timolol maleate 0.5% in Glaucoma and Ocular Hypertension, sponsored by Allergan. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-04-23.
Sponsored by Allergan (part of AbbVie) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing timolol in Glaucoma — none open to participants now, none under way, none of them phase 3. Timolol · Glaucoma.
Among the 28 studies testing timolol in Glaucoma, this one is the 4th largest by enrollment, is one of 2 that started in 2008, is one of 13 in phase 4, and was the 7th registered.
1,419 studies on the registry are indexed under Glaucoma; 221 are open to participants now.
Browse Glaucoma studies →None of the 28 studies testing timolol in Glaucoma is open now. The open studies under Glaucoma, anywhere →
Timolol: first FDA approval 1978 (TIMOPTIC), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 155 Glaucoma studies recruiting now, 113 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 2 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 204 is above the median of 61 across 964 interventional studies indexed under Glaucoma.
Median enrollment 60 across the 28 interventional studies. Of the 24 that completed or were terminated, 8 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 28 have an industry lead sponsor. The 10 most frequent:
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
34 studies in Glaucoma by AbbVie: none open now, none under way, none of them phase 3. Of 33 finished, 23 (70%) have results posted.
Among the 34 studies in Glaucoma by AbbVie, this one is the 14th largest by enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2008, is one of 12 in phase 4, and was the 11th registered.
AbbVie’s Glaucoma studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 28 studies testing timolol in Glaucoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 34 in Glaucoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Efficacy and safety evaluation of Combigan with timolol when each is used as adjunctive therapy to Xalatan in subjects with glaucoma or ocular hypertension.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Combigan® (fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%) adjunctive to Xalatan® (latanoprost 0.005%)
Drug: Fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% · Drug: latanoprost 0.005%
Timolol maleate 0.5% adjunctive to Xalatan® (latanoprost 0.005%)
Drug: timolol maleate 0.5% · Drug: latanoprost 0.005%
1 drop of fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% taken approximately 12 hours apart, up to 2 times a day.
Also known as: Combigan®
1 drop of timolol maleate 0.5% taken approximately 12 hours apart, up to 2 times a day.
Also known as: Timpoptic®, Timoptol®
1 drop of latanoprost 0.005% once nightly.
Also known as: Xalatan®
Mean Intraocular Pressure (IOP) at 10 AM at Week 12
Mean IOP at 10 AM at week 12. IOP is a measurement of the fluid pressure in the eye.
Time frame: Week 12
Mean Intraocular Pressure (IOP) at 10 AM at Week 6
Mean IOP at 10 AM at week 6. IOP is a measurement of the fluid pressure inside the eye.
Time frame: Week 6
Mean Intraocular Pressure (IOP) at 8 AM at Week 12
Mean IOP at 8 AM at week 12. IOP is a measurement of the fluid pressure inside the eye.
Time frame: Week 12
Mean Intraocular Pressure (IOP) at 8 AM at Week 6
Mean IOP at 8 AM at week 6. IOP is a measurement of the fluid pressure inside the eye.
Time frame: Week 6
Number of Subjects With Adverse Events
Number of subjects with adverse events, defined as any untoward medical occurrence in a subject, during the study (reported through the week 12 visit).
Time frame: Week 12
| Milestone | Combigan® | Timolol Maleate 0.5% |
|---|---|---|
| Started | 102 | 102 |
| Completed | 95 | 96 |
| Not completed | 7 | 6 |
Mean IOP at 10 AM at week 6. IOP is a measurement of the fluid pressure inside the eye.
| Millimeters of mercury (mmHg) | Combigan® | Timolol Maleate 0.5% |
|---|---|---|
| Mean Intraocular Pressure (IOP) at 10 AM at Week 6 | 15.9 ± 3.10 | 16.7 ± 2.78 |
Mean IOP at 10 AM at week 12. IOP is a measurement of the fluid pressure in the eye.
| Millimeters of mercury (mmHg) | Combigan® | Timolol Maleate 0.5% |
|---|---|---|
| Mean Intraocular Pressure (IOP) at 10 AM at Week 12 | 15.1 ± 2.59 | 16.9 ± 2.46 |
Mean IOP at 8 AM at week 12. IOP is a measurement of the fluid pressure inside the eye.
| Millimeters of mercury (mmHg) | Combigan® | Timolol Maleate 0.5% |
|---|---|---|
| Mean Intraocular Pressure (IOP) at 8 AM at Week 12 | 17.0 ± 2.55 | 17.7 ± 2.58 |
Mean IOP at 8 AM at week 6. IOP is a measurement of the fluid pressure inside the eye.
| Millimeters of mercury (mmHg) | Combigan® | Timolol Maleate 0.5% |
|---|---|---|
| Mean Intraocular Pressure (IOP) at 8 AM at Week 6 | 17.3 ± 2.87 | 17.8 ± 3.17 |
Number of subjects with adverse events, defined as any untoward medical occurrence in a subject, during the study (reported through the week 12 visit).
| Participants | Combigan® | Timolol Maleate 0.5% |
|---|---|---|
| Number of Subjects With Adverse Events | 15 | 13 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Combigan® | — | 0/102 (0%) | 0/102 (0%) |
| Timolol Maleate 0.5% | — | 2/102 (2%) | 0/102 (0%) |
| Event | Combigan® | Timolol Maleate 0.5% |
|---|---|---|
| Acute exacerbation of COPDRespiratory, thoracic and mediastinal disorders | 0/102 | 1/102 |
| Bacterial bronchitisInfections and infestations | 0/102 | 1/102 |
| Age, Continuous(years) | Combigan® | Timolol Maleate 0.5% | Total |
|---|---|---|---|
| Median | 64.5 (30.1 to 87.0) | 65.9 (29.8 to 88.9) | 65.4 (29.8 to 88.9) |
| Sex: Female, Male(Participants) | Combigan® | Timolol Maleate 0.5% | Total |
|---|---|---|---|
| Female | 57 | 45 | 102 |
| Male | 45 | 57 | 102 |
The record gives a start of Jul 2008, a primary completion of Dec 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2011, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Timolol